Amplia Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is April - March.

Millions AUD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	-7.71	-6.57	-4.5	-6.24	-3.64
Depreciation & Amortization	0.09	0.09	0.09	0.07	0
Stock-Based Compensation	0.13	0.08	0.09	0.21	0.06
Other Operating Activities	0.14	0.06	0	0	-0
Change in Accounts Receivable	-1.1	-0.67	-2.04	0.68	-0.83
Change in Accounts Payable	-0.28	0.13	1.25	-0.01	0
Operating Cash Flow	-8.73	-6.89	-5.13	-5.29	-4.4
Capital Expenditures	-0.03	-0	-0	-0.02	-0.01
Other Investing Activities	-0.06	-	-	-0.04	-0.01
Investing Cash Flow	-0.1	-0	-0	-0.06	-0.03
Long-Term Debt Issued	-	-	1.47	-	2.1
Long-Term Debt Repaid	-0.07	-1.55	-2.18	-0.06	-
Net Debt Issued (Repaid)	-0.07	-1.55	-0.71	-0.06	2.1
Issuance of Common Stock	27.88	17.28	0	0.02	16.27
Other Financing Activities	-1.88	-1.41	-0.06	-0.04	-1.18
Financing Cash Flow	25.94	14.32	-0.77	-0.08	17.19
Foreign Exchange Rate Adjustments	-0.12	0.05	0.03	0.08	-0
Net Cash Flow	16.99	7.48	-5.87	-5.35	12.76
Free Cash Flow	-8.77	-6.89	-5.13	-5.31	-4.42
Free Cash Flow Margin	-159.68%	-182.04%	-115.20%	-446.19%	-222.68%
Free Cash Flow Per Share	-0.02	-0.02	-0.03	-0.03	-0.03
Cash Interest Paid	-	0.08	0.06	0.04	-
Cash Income Tax Paid	-	-3.18	-2.41	-1.84	-1.14
Levered Free Cash Flow	-6.05	-4.77	-3.59	-2.99	-3.07
Unlevered Free Cash Flow	-6.03	-4.74	-3.54	-2.95	-3.07
Change in Working Capital	-1.39	-0.53	-0.8	0.67	-0.82